Immunovant (IMVT)
(Delayed Data from NSDQ)
$30.92 USD
+0.41 (1.34%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $30.92 0.00 (0.00%) 7:14 PM ET
4-Sell of 5 4
D Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Immunovant, Inc. [IMVT]
Reports for Purchase
Showing records 41 - 60 ( 105 total )
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Development of IMVT-1402 is Picking Up Steam; PT Up to $27; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Updated Thoughts on the Anti-FcRn Market; A Comprehensive Slide Deck
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Updated Thoughts on Immunovant; Raise PT to $26; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Gearing up for Multiple Readouts in 2023; Price Target Up to $21; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Strategy Gains Some Clarity with Addition of IMVT-1402; Maintain Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Immunovant Gives Roses to CIDP and Graves Disease; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Immunovant Set to Lift the Curtain on New Indications and a New Phase 3 Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Batoclimab Set For Phase 3 in TED With More to Come; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department